Torrent Pharmaceuticals Recalls Select Semalix Injection Batches Following Dr. Reddy's Notification
Torrent Pharmaceuticals is voluntarily recalling select batches of its Semalix semaglutide injection pens, specifically 2 mg and 4 mg doses manufactured by Dr. Reddy's Laboratories (DRL), following a recall notification from DRL due to out-of-specification issues with an active ingredient. Torrent stated there is no risk to patients currently using the treatment, and other Semalix products, including oral formulations and injections from other manufacturers, remain unaffected. DRL is investigating the cause and taking measures to ensure product quality.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. Coverage leans balanced overall (Left 0%, Centre 100%, Right 0%). Overall sentiment is neutral (50/100). Lens Score 33/100 — low public interest.
Outlets analysed (first-hand measurement by TBN's Bias Engine):
- economictimes— balanced framing, neutral sentiment
- news18— balanced framing, neutral sentiment
AI Analysis
The articles present a straightforward corporate and regulatory update without political framing. Both sources focus on the companies' statements regarding product recall and safety measures, reflecting a neutral business and health regulatory perspective. There is no evident political viewpoint or partisan framing in the coverage.
The overall tone across the articles is neutral and factual, emphasizing precautionary measures and patient safety. While the recall indicates a quality issue, the companies stress no current risk to patients and ongoing investigations, resulting in a balanced and reassuring sentiment without alarm or criticism.
How 2 sources covered this story
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.